Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
VIVITROL (Naltrexone extended-release injectable suspension)
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Dependence
1 trial -
Venclyxto 100 mg film-coated tablets, Azacitidine Kabi 25 mg/mL powder for suspension for injection
The George Institute
acute myeloid leukemia
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Azacitidine Mylan 25 mg/mL powder for suspension for injection, Azacitidine Mylan 25 mg/mL powder for suspension for injection, pevonedistat hydrochloride, Venclyxto 100 mg film-coated tablets
Takeda
Acute Myeloid Leukemia
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets
Lacuna Pharma Pty Ltd
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, PIVEKIMAB SUNIRINE, Venclyxto 100 mg film-coated tablets
AbbVie Deutschland GmbH & Co. KG
CD123 positive Acute Myeloid Leukemia
1 trial -
ZEULIDE 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée, Elacestrant
The George Institute
Breast cancer
1 trial -
megestrol acetate oral suspension + serplulimab + SOX
The First People's Hospital of Lianyungang
Stage III Gastric Cancer
1 trial -
500 mg GLPG1837 as oral suspension
Lakefront Biotherapeutics NV
Healthy
1 trial -
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
infection
1 trial -
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS
Lacuna Pharma Pty Ltd
Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.
1 trial -
Atovaquone Oral Suspension
United Therapeutics Europe Ltd
Locally Advanced Non-Small Cell Lung Cancer
1 trial -
Bioavailability study of stiripentol after single oral administration of two different formulations (capsule and oral suspension) in 24 healthy subjects
Biocodex
Dravet syndrome
1 trial -
Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditions
BIAL - Portela & Ca
No medical condition.
1 trial -
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design
Helsinn Birex Pharmaceuticals
Healthy volunteers
1 trial -
Cefdinir for oral suspension 250 mg/5mL
Teva Pharma GmbH
Healthy
2 trials -
Cefprozil for oral suspension 250 mg/5 mL
Teva Pharma GmbH
Healthy
2 trials -
GLPG1205 single ascending doses, oral suspension
Lakefront Biotherapeutics NV
Healthy
1 trial -
GLPG3667 oral suspension
Lakefront Biotherapeutics NV
Healthy
1 trial -
GLPG4059 oral suspension
Lakefront Biotherapeutics NV
Healthy
1 trial -
GLPG4399 oral suspension
Lakefront Biotherapeutics NV
Healthy
1 trial -
MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension
Pari Pharma GmbH
Familial Hemophagocytic Lymphohistiocytosis (FHL)
1 trial -
Semaglutide Extended-release for Injectable Suspension, 1 mg
BRIGHT MINDS BIOSCIENCES INC.
Diabetes Mellitus, Type 2
1 trial -
TAK-831 Oral Suspension
NEUROCRINE BIOSCIENCES INC
Schizophrenia, Cerebellar Ataxia
1 trial -
TAK-915 suspension
Takeda
Healthy Volunteers
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources